• If you are wondering whether Novo Nordisk's current share price still reflects its long term potential, the key question is how its fundamentals stack up against that price.
• The stock last closed at US$39.32, with returns of 6.5% over 7 days and 3.6% over 30 days, but a 24.9% decline year to date and a 37.0% decline over the past year, which may suggest that expectations and perceived risk have shifted.
• These moves have put a spotlight on Novo Nordisk in broader market commentary and investor discussions, especially as investors reassess large healthcare names after a period of mixed sentiment. While short term headlines come and go, they provide useful context for understanding why the share price sits where it is today relative to recent history.
• On Simply Wall St's valuation checks, Novo Nordisk scores a 5 out of 6 on its valuation score. This sets up an interesting comparison across discounted cash flow, multiples, and other methods, with an even more helpful way to think about valuation coming at the end of this article.

Approach 1: Novo Nordisk Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back to today to reflect risk and the time value of money.

For Novo Nordisk, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model based on cash flows reported in Danish kroner. The latest twelve month free cash flow stands at DKK 52,097.2m, or about DKK 52.1b. Analyst estimates and subsequent extrapolations suggest projected free cash flow of DKK 111,085.5m, around DKK 111.1b, by 2030. Intermediate annual projections between 2026 and 2035 form the backbone of the model.

Discounting those projected cash flows back to today produces an estimated intrinsic value of US$108.76 per share. Compared with the recent share price of US$39.32, this implies a 63.8% discount, which indicates that Novo Nordisk is trading well below this particular cash flow based estimate of value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 63.8%. Track this in your watchlist or portfolio, or discover 57 more high quality undervalued stocks.

Approach 2: Novo Nordisk Price vs Earnings

For a profitable company, the P/E ratio is a straightforward way to relate what you pay for each share to the earnings that support it. It helps you see how much the market is willing to pay for each dollar of current earnings, which is often where investors start when comparing established businesses.

What counts as a “normal” P/E depends a lot on growth expectations and risk. Higher expected earnings growth and lower perceived risk can support a higher multiple, while slower growth or higher uncertainty usually point to a lower, more conservative P/E.

Novo Nordisk currently trades on a P/E of 10.66x. That sits below the Pharmaceuticals industry average of about 16.81x and also below a peer average of 18.00x. Simply Wall St’s Fair Ratio for Novo Nordisk is 25.65x, which is a proprietary estimate of what the P/E might be given factors such as earnings growth, profit margins, industry, market cap and company specific risks. This Fair Ratio is more tailored than a simple industry or peer comparison, because it attempts to adjust for the company’s own profile rather than assuming all firms should trade at the same multiple. With a Fair Ratio above the current P/E, Novo Nordisk appears undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Novo Nordisk Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in. They give you a simple way to attach a clear story about Novo Nordisk to your numbers by linking your view of its future revenue, earnings and margins to a financial forecast, a Fair Value, and a decision on whether the current share price looks high or low.

On Simply Wall St, Narratives sit inside the Community page and are easy to use. You can quickly set your own assumptions, see the implied Fair Value next to today’s price, and update that view as fresh news, earnings or guidance arrive without rebuilding a model from scratch.

For Novo Nordisk, one investor Narrative currently anchors on a Fair Value of about US$65.50 per share, while another sits closer to US$95.00. This shows how two people can look at the same company, apply different expectations to the GLP-1 franchise, competition and new therapies, and reach different yet structured conclusions that help them decide what to do when price moves.

Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.